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Abstract 
In April 2004, Copenhagen Business School opens a centre for research on biotech 
business. Biotech Business includes a number of senior and junior researchers from 
CBS. Initially the centre takes its point of departure in four projects included in the 
research program on Competence, Organisation and Management in Biotech Industries 
(COMBI). Starting in March 2004, COMBI is funded jointly by The Danish Social 
Research Council, firms and organisations in the Danish biotech industry and CBS. This 
presentation refers exclusively to four COMBI projects. 
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Objectives, issues and activities 
Programme objectives 
The research programme on Competence, Organisation and Management in Biotech Industries 
(COMBI) will study Danish biotechnology with the following main objectives: 
• To generate new data that will allow a comprehensive analysis of Danish biotechnology and 
its exchange with its key environment of public science, venture capital and the 
pharmaceutical industry. 
• To develop and apply novel approaches in quantitative analysis of e.g. R&D profiles, 
innovation networks, and the value of patents. 
• To expose and develop COMBI research in an ongoing dialogue with the Danish biotech 
community on issues of managing science-based firms and on trends in the key context of the 
sector provided by venture capital, public science and the pharmaceutical industry.  
• To enhance theoretical understanding of issues of management, organisation and 
competitiveness in science-driven sectors. 
 
Motivations 
• The Øresund Region, and Denmark in particular, holds one of several agglomerations of 
biotech firms that have emerged in the US and in Europe since the mid 1980s. Like their 
counterparts in other regions, Medicon Valley (MV) firms have evolved through a complex 
interaction between science opportunities, venture capital and markets for research and for 
research-based products. This project will produce a long overdue systematic mapping and 
analysis of the MV population of firms in terms of these interactions. This mapping will be 
of interest not only to DBF firms, but also to the VC sector financing them, to science 
institutions reflecting on new strategic mandates, and to policy institutions. 
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• Biotechnology, as a wholly science-driven business, brings out with unusual clarity a set of 
issues that increasingly appear also across a broader spectrum of industries. That includes 
issues pertaining e.g. to i) the management of entirely immaterial/ knowledge-based 
processes, ii) difficulties in assessing the value of its assets and products and hence in 
mobilising venture capital, iii) challenges in organising and iv) defining the role of public 
science in industrial innovations. Biotechnology is a “laboratory” allowing us to study in a 
pure and early form these issues, the implications of which go far beyond the specific biotech 
sector. 
• Precisely for this reason biotech is a highly informative field for applying and developing 
theories targeted at these broader issues of knowledge-based firms and economies. That 
includes theories on the role of science in innovation and firm performance, theories on IPR 
and appropriablity or inter-organisational co-ordination.  
 
Definitions and focus 
Biotechnology has become an ambiguous term and needs delimitation. In its modern version 
biotechnology refers to a body of techniques and technologies applying genetics, immunology, 
molecular, cellular structural biology for discovery and development of new products. It is 
increasingly being applied in different industrial sectors, with pharmaceuticals being by far the 
largest arena for industry-specific biotechnology (Allansdottir et 
al 2002; Audretsch 2000). 
Traditional sectors like agriculture and food processing 
(ingredients) are increasingly building their industry specific 
knowledge on biotechnology, and it is also becoming the 
knowledge basis for new industries, including biomaterials and 
environmental technologies. Of particular importance is the 
emergence of a new industry of firms undertaking biotech-based 
R&D without further downstream activities, normally referred 
to as Dedicated Biotech Firms (DBFs). They deliver inputs to 
R&D of pharmaceuticals, and they develop tools and 
methodologies for biotech R&D.  
Relationships between industries 
and biotech knowledge
We use the term “biotech sector” to denote both its core of DBFs
substantially on biotechnology and having at the same time further
specific industries (i.e. including pharmaceutical firms and produc
industrial processes like Novozymes, Danisco, or Chr. Hansen e
includes organisations in public research and health-care in cases w
involve biotechnology or rely on its underlying knowledge base. 
Finally, the term “biotech community” expands the delimitatio
include associations like Medicon Valley, the Øresund Food net
and bodies of public administration with a focus on biotech. 
As evident from the project descriptions below, COMBI resear
focused on several major areas of the Danish biotech sector
particular emphasis is placed on the study of DBFs.  
 
Projects and their synergies  
COMBI research is organised into four distinct research projects:  
• Industry and firm dynamics in Danish biotech (= BIO-DYN
developments of DBFs, and their key external relationshFo
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universities and pharma-firms. The project generates and analyses quantitative data from its 
proprietary construction of a comprehensive database of all Danish biotech firms, referred to 
as DABIT. 
• Organisation and management in biotech firms (= ORG-MAN, c/o Jesper Norus) studies 
research management and strategy in DBFs, using new structured case-observations and 
quantitative data from DABIT. 
• Knowledge protection and diffusion in university-corporate partnerships in biotechnology (= 
UNI-COR, c/o Lee Davis) studies the implications of university-corporate partnerships as 
regards the commercial development of valuable new ideas in biotechnology. The project is 
based on quantitative analysis of proprietary, new data from a survey of public scientists in 
biotechnology. Data is exchanged with DABIT records.  
• Understanding the profitability of biotechnology inventions with the help of indicators (= IN-
PROF, c/o Markus Reitzig) develops an empirical test of patent indicators as value measures 
of biotechnological inventions in the structural form. 
The theoretical and methodological underpinning of each project will be presented in Section II. 
In this introduction, we only discuss their shared point of departure. The key characteristics of 
the biotech sector, and the analytical issues addressing them, may be summarised as follows: 
1. Having research as their main activity, biotech firms are directly exposed to the turbulence of 
global advances in the life sciences. Advances in basic research directly generate changes in 
the agenda of applied research. The inherent creative destruction of this research frontier 
(Darby and Zucker 2001) translates almost immediately into instability of both strategies and 
business models in biotech firms (Stankiewicz 2002).  
2. Consequently the biotech industry is highly dependent on early and fast access to scientific 
novelties, making their linkage to early insights a key concern. Studies indicate that public 
science may provide this early insight (McMillan et al 2000), as long as it operates at the 
frontier of global science and is well connected to the biotech industry. It matters therefore to 
have both top quality public science and to have it effectively linked up to the biotech 
industry (Valentin 2000).  
3. This linkage takes different forms and varies across countries. The US linkage-model of 
“scientists-turning-entrepreneurs” (Zucker et al 1994) appears less frequently in continental 
Europe, as does licensing of patents based on university research in the life sciences (Fuchs 
2003). Legal regulation affecting patenting propensity amongst university scientists may 
therefore significantly affect their outward flow of opportunities towards the biotech industry 
(Mowery et al 2001). That is the reason why one COMBI project undertakes a thorough 
study of appropriability of university science, including its feedback effects on the agenda of 
public science. 
4. Public science, however, is far from being the only source of “early insights”. With the 
increasing role of effective research technologies, connectivity between DBFs with different 
specialisations assumes growing importance. The division of labour in biotechnology no 
longer takes the form of a simple vertical disintegration, where DBFs feed discoveries into 
the processing and commercialisation machinery of big pharma. DBFs bundle discovery 
activities into several quite different business models (e.g. platforms, pipeline orientations 
etc.), or they focus on specific research tools or specialised research services to be used by 
other DBFs and by big pharma in their discovery activities. Complex horizontal and vertical 
relationships are developing between DBFs (Arora et al 2001). As a consequence, it matters 
little that a region – like the Copenhagen area – has a concentration of biotech firms. What 
matters is really what type of biotech industry we are talking about: How is it specialised 
amongst the many different DBF models? What types of inter-linkages and synergies grow 
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out of this specialisation between firms and between the DBF industry and its infrastructure 
(e.g. public science, venture capital etc.)? The more exact profile on these dimensions of a 
specific biotech industry is critical for its long-term development (Casper 2000) 
(Braunerhjelm et al 2000). Mapping and analysing the Danish DBF industry in these terms 
appears not to have been undertaken in any previous exercise. Given the significance of 
biotechnology for the Danish economy and its policy priority, this exercise is long overdue, 
and it will constitute one of the key research activities in COMBI. 
5. Given the high uncertainties of biotech R&D, venture capital, not surprisingly, has come to 
play a key role. To minimise risks, venture capital increasingly seems to be directing 
investment flows away from the early, high-risk discovery phases of biotechnology. Instead 
they focus further downstream, often requiring “proof of concept” to have been reached 
before investing. Improved methods to analyse both risks and value potential of biotech firms 
would facilitate venture financing to more firms in these critical early stages (Gompers and 
Lerner 1998). 
These characteristics and issues are highly interconnected, and the COMBI research agenda 
should reflect these connections. Even though COMBI has four distinct projects they 
nevertheless form one coherent program, studying closely connected phenomena in the biotech 
sector and analysing them from related theoretical points of departure. Above all, what gives 
coherence and synergy between projects is that they address the same underlying issues. The 
table below gives examples of four such issues (although more could be added) and examples are 
presented of how they are addressed in each project. 
How issues are addressed in each COMBI project Issues appea-
ring across 
all projects BIO-DYN ORG-MAN UNI-COR IN-PROF 
What types of 
biotech 
companies are 
profitable over 
time? 
 
Mapping which 
companies 
survive and 
prosper over 
time (which 
factors are 
important?) 
Development of 
production skills 
and 
manufacturing 
capabilities  
Do companies that 
cooperate heavily with 
university scientists 
tend to succeed better 
than those that don’t? 
Are there specific 
differences between 
corporations in the 
Øresund region and 
other firms? 
What types of 
biotech 
inventions are 
profitable over 
time? 
Mapping the 
evolution of 
different 
categories of 
biotech 
inventions 
Understanding 
how markets are 
created for 
research outputs 
of DBFs 
How have university 
scientists contributed 
to these successes? 
Are there specific 
differences between 
therapeutic targets 
and other relevant 
biotechnology 
inventions?  
What types of 
collaborations 
foster success? 
Mapping effects 
of different types 
of collaborations 
on company 
survival rates 
Development and 
management of 
knowledge in 
inter-
organizational 
networks 
How can partnerships 
between universities 
and companies best 
be structured? 
Are patents held by 
biotech firms that 
collaborate with 
public researchers or 
other firms more 
valuable? 
What are the 
implications for 
science and 
technology 
policies? 
What 
government 
incentives are 
associated with 
increased 
success rates? 
What government 
incentives best 
support 
successful 
policies? 
What are the larger 
societal implications of 
increased 
collaboration between 
public scientists and 
biotech firms?  
How does the 
adjustment of 
patentability 
requirements affect 
innovation 
incentives? 
 
 
 
 
Furthermore, projects have been selected and designed so that they together cover different 
stages of biotech R&D, going from discovery (e.g. of new therapeutic targets) through 
development, until resultant patents are claimed and have their value assessed. The figure below 
positions each project in this sequential logic. The figure also shows how data creation in any 
one COMBI project benefits from being informed and combined with data from other projects.  
 
Sequences of discovery, development and commercialisation as covered in different 
COMBI projects. Exchange and combinations of data sources between projects 
 
 
 
 
 
  7  
Discovery
Formation 
of firms to 
pursue 
targeted 
R&D
Managing 
firms and 
projects
Generating  
and assessing 
value of resul-
tant patents
ORG-MAN
BIO-DYN
IN-PROFUNI-COR
Sequence of 
biotech discovery, 
development and 
commercialisation 
(patenting)
COMBI projects
Combinations of 
new data created 
in different 
projects
Survey infor-
mation to 
data-base 
combinations
Case-data to 
data-base 
combinations 
Various combinations 
with patent data 
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Who participates 
The program draws on a substantial body of work undertaken not only by CBS researchers but 
also by managers and staff from nine additional different firms and research organisations. 
CBS researchers include three associate professors and one assistant professor, each affiliated 
with one of the four above projects Their CVs are presented in Appendix D. They come from 
two different CBS departments and represent specialised research experience in economics, 
organisational analysis, and innovation studies.  
These four CBS researchers are well connected to the global research environment on the 
management, organisation and economics of biotech. Several internal visiting scholars will join 
us for work on specific research issues. 
When the program is ready to begin its work (Jan.2004) this team will be extended with: 
• Two post docs, one of whom is financed by CBS internal funding to match the one post doc 
applied for from LOK funding. 
• Five PhDs, three of whom are financed jointly by Novo Nordisk and the Fenix consortium of 
Danish and Swedish firms and research organisations. One PhD is financed by CBS internal 
funding to match some of the industry funding specifically made available for PhD training 
in issues relating to biotech business studies. Moreover, one PhD is affiliated though a 
collaboration agreement with Risø National Laboratories (Research Group on Technology 
Scenarios). 
The nine partner organisations represent a variety of issues and experience. Several DBFs are 
involved, as are venture capital firms and organisations with particular mandates for contributing 
to Danish biotechnology.  
• Pipeline Biotech 
• NOVO A/S 
• Bioteknologisk Institut 
• BankInvest 
• Medicon Valley Academy 
• Scan Balt 
• The Fenix consortium of Danish and 
Swedish firms and research 
organisations, including NOVO Nordisk 
• Risø National Laboratory 
 
The PhD collaboration with Risø has not been included as part of program funding, since this 
would violate LOK requirements not to include other public funding as part of co-financing. 
Activities and programme management 
The key activities of the programme are to carry out the four research projects outlined in 
Section II of this proposal. However, this activity will involve substantial interaction with the 
above partners from the Danish biotech community. From them, data and experience will be 
extracted and analysed, and each firm receives feedback from the research to which they have 
contributed. On an informal level there will be an ongoing exchange within each project. 
Furthermore, regular seminars will provide a meeting place for programme researchers and the 
Danish biotech community. Here, progress in research will be reported, international guest 
researchers will present recent work, and programme partners may share their experiences. 
Annual one-day conferences will be arranged, in the final year of the programme transformed to 
an international conference on the management and economics of biotechnology. We hope to 
make these shared arrangements an interesting forum for researcher-practitioner dialogue, and a 
substantial share of the sub-budget serves that purpose.  
Research stays abroad are planned where substantial programme benefits may be expected, as in 
the cases of Jesper Norus visiting Prof. David Finegold, Keck Graduate Institute of Applied Life 
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Sciences, Claremont Colleges, California, or Markus Reitzig further developing his econometric 
modelling of biotech values in collaborative work with Prof. Bronwyn Hall (UC Berkeley) and 
Prof. Timothy Devinney (Australian Graduate School of Management). 
The programme will be directed by Finn Valentin. An advisory board will be established with 
representatives from partner companies and institutions. Annual meetings will be held between 
the advisory board, the senior scientists and the program director. 
 
 
 
 
 
 
 
 
Research projects in the COMBI programme 
 
Industry and firm dynamics in Danish Biotech (BIO-DYN)  
Finn Valentin  
Objectives 
This project (BIO-DYN) contributes to our understanding of how science-based firms 
emerge, perform and develop. The project pursues the four following objectives: 
1. To improve our understanding of science-based firms and industries by analysing 
Danish biotech firms in terms of their emergence, development, performance, and 
their external linkages to the wider biotech sector 
2. For this purpose to build a complete panel database of Danish DBFs, mapping each 
firm in terms of its performance, internal characteristics, and main external relations 
since its establishment and onwards. This DAnish BIotech Database is referred to as 
DABIT. 
3. Using the database to address theoretical issues at the firm-level and at the mezzo-
level of relationships between DBFs and other key actors within the biotech sector, 
e.g. universities, venture capital, pharmaceutical firms. DABIT data will feed not 
only into the three BIO-DYN sub-projects summarised below but also into other 
projects within the COMBI research programme.  
4. To subsequently regularly update the database to allow ongoing monitoring of and 
further research on Danish biotechnology.  
Scientific context and motivation 
Current advances in the literature provide a general basis for the more confined issues 
presented below for each of the sub-projects:  
Direct utilisation of recent research plays an increasing role for industrial R&D in 
technology intensive sectors (McMillan et al 2000), stimulating analysis of science as 
an endogenous component in economic development (Rosenberg 2000). 
Science translates into economic activity contingent on institutional arrangements. 
Institutions shape e.g. how spillovers from academic science migrate into private R&D, 
or how inventions get connected to finance (Audretsch and Stephan 1999). Adequate 
venture capital (VC) in particular has been acknowledged as essential for the success of 
US firms in biotechnology (Henderson et al 1999). But the exact ways in which 
characteristics of VCs (size, experience, specialisation), shape and influence investment 
targets have barely been addressed in systematic research (Nilsson 2000). Similarly, the 
effects of specific institutional arrangements linking academic science to industry are 
beginning to be explored (Geuna 1999; Larédo and Mustar 2001; Valentin 2000). 
BIO-DYN will contribute to further theoretical understanding of the organisation and 
the economics of science-based business, based on the mapping of how an entire 
national science-driven sector emerges and develops.  
Empirical design 
DABIT maps all Danish DBFs (app. 80) on a broad set of attributes, e.g. 
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• Type of origin (spin-offs from university departments, from other companies etc.) 
• Activity level (staff, number of scientists) 
• Main type of biotech activity (tool providers, platform, pipeline etc.) 
• Research field (disciplines, research specialisation, therapeutic targets) 
• Collaboration with external research (in universities, other firms etc) 
• Venture capital generated (volume and sources) and burned   
• Output: Patents, publications etc.  
• Sources of revenue (royalties, research services, products) 
 
With archival data these parameters will be reconstructed for each firm for each year 
since the firm’s establishment (in most cases meaning 1995 onwards), and of course 
updated systematically. DABIT will draw on multiple sources of data, benefiting from 
the general high level of documentation that characterises pharma-related activities (e.g. 
rich patent information and scientific publications in highly effective search 
architectures, as exemplified in e.g. (Gittelman and Kogut 2003)). Annual reports from 
firms tend to be highly informative. To this may be added conventional sources like 
firm records in e.g. The Danish Commerce and Companies Agency. Specific 
information not available through these channels is retrieved through interviews. This 
configuration of data, and its coverage of Danish DBFs, exceeds what is offered by 
existing proprietary databases.  
In addition to mapping firm-level characteristics, for a number of variables the unit of 
observation will be the single project within each DBF, applying the methodology 
found in e.g. (Henderson and Cockburn 1996). An average of 5-10 projects per firm will 
generate 400-800 data-points on each variable. 
An essential condition for accessing and interpreting information on individual DBFs is 
the close collaboration with the biotech community. This is where the collaborative 
arrangement of COMBI will offer a unique opportunity for a more fine-grained 
mapping. 
DABIT’s data architecture facilitates analysis with both panel and structural 
approaches, and patterns of morphology of individual firms may be identified. 
Correspondence and exchange with related database projects in other countries will be 
pursued (e.g. the Siena Univerity BID-database on global biotech collaborations 
(Orsenigo et al 2001), or the Ohio-Sweden comparative project (Carlsson 2002). This 
potential for a comparative exploitation of DABIT is an attractive platform for research 
collaboration with the international research frontier in this particular field (Fuchs 
2003). 
Analysis of DABIT data will allow analysis of a variety of issues. Within the funding 
from this proposal BIO-DYN will use the database for analysis in the three following 
sub-projects. 
Subprojects  
Sub-project 1: Science-based businesses and theories of the firm 
CBS allocates one PhD to this sub-project. 
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Competence-based theory of the firm invites us to examine the basis for value-creation 
in biotech firms. In many respects the knowledge resources of DBFs, in their 
constitutive forms, resemble what is found on “factor markets” of advanced public 
science. Where this is the case, how do biotech firms nevertheless achieve a Penrosian 
transformation of public knowledge into value creating capabilities? Is differentiating 
performance of DBFs in research output (and timing) driven by uniquely co-specialised 
DBF-internal bundling of competencies (Foss and Mahnke 2003), as a competence-
based view would have it?  Or is it rather driven by transaction cost advantages, derived 
from superior assessment of external opportunities and from the ability to access them 
in shifting collaborations and consortia? The latter approach would see superior DBF 
performance as based on transaction cost advantages, along the lines recently suggested 
by (Amit and Zott 2001) or (Dyer and Singh 1998). These two theoretical foundations – 
competence-based views and transaction costs – bring out very different interpretations 
of science-based value creation in DBFs. DABIT offers opportunities for analysis from 
either perspective.  
Sub-project 2: Assessing value and potentials of DBF 
Strategy-oriented analysis referred to in Sub-project 1 also may inform studies of 
venture capital financing of DBFs. There is a shortage of analytical approaches guiding 
valuation of DBFs in their early stages. Consequently, venture capital tends to focus on 
DBFs beyond the stage of “proof of concept”, while investors find it prohibitively 
difficult to assess the potential value of inventions in their early stages. 
With the patent information and the scientific publication details available in DABIT, 
we may apply standard bibliometric tools (Jaffe and Trajtenberg 2002; Grupp 1998) to 
explore if the value potential of DBFs may be indicated at earlier stages. Further 
bibliometric analysis would examine how the knowledge configuration and/or the 
external network patterns of DBFs (as reflected e.g. in co-authorships) relate to their 
profitability. This analysis would draw on tools going beyond the standard bibliometric 
repertoire, using methodologies we have introduced in recent work (Valentin and Jensen 
2003a). 
Sub-project 3: A systems perspective on the Danish biotechnology 
This sub-project addresses issues at the level of “systems of technologies” (Stankiewicz 
2002; Carlsson 2002), inquiring how the specific Danish biotech technology system 
affects patterns at both firm and industry levels. I.e. how individual firms extract 
advantages, or drawbacks, from their surrounding system of innovation, as reflected e.g. 
in the composition of their networks of innovation (applying tools for quantitative 
network analysis presented in (Valentin and Jensen 2002; Valentin and Jensen 2003b))? 
How patterns of specialisation in a research-based industry co-evolve with its 
institutional framework of science and capital markets? What sources of origin are 
particularly important for spinning off Danish DBFs e.g. universities or other pharma- 
or biotech firms? What research fields are pursued, and which type of activity (tool 
providers, platforms etc.) is their objective? How does revenue formation (type and 
timing) vary across different categories of DBF activities? How does infusion of new 
venture capital affect DBFs in terms of focusing their business models? 
Key elements in the national framework of Danish biotech are currently undergoing 
change: New regulations apply to university patenting, and recent reports from the 
universities indicate effects on commercialisation of academic research to be 
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significant, although very different from those intended in the legislation. From another 
angle, venture capital increasingly brings biotech firms to focus their research 
programmes more directly at highly specific revenue targets, profoundly affecting their 
scope of research. As BIO-DYN will be carried out over the next three years, we are 
offered a rare opportunity to observe how the maturation of a science-driven industry 
may be shaped through its profound interaction with both university science and with 
venture capital institutions.   
 
Knowledge protection and diffusion in university-corporate 
partnerships in biotechnology (UNI-COR).  
Lee Davis 
 
Purpose 
With the rapid commercial development of the biotechnology industry, questions 
concerning what role academic scientists should play, and how best to organize and 
manage university-corporate partnerships in new product development, acquire new 
urgency. This project will explore the appropriability aspects of these choices for the 
commercial development of biotechnology in Denmark, and their implications for 
scientists, the biotechnology companies, and society. To investigate how scientists 
contribute to the biotech industry in Denmark, and the effects of these collaborations, 
we will conduct quantitative analysis based on questionnaire responses from a survey of 
scientists in Danish universities and public institutions. 
Motivation 
Academic research in this area is informed by a central “puzzle” (e.g. Dasgupta and 
David, 1994, Mansfield & Lee, 1996, Narin et al., 1997, McMillan et al., 2000). 
University scientists work under a collegiate reputation-based reward system. Success is 
tied to priority – coming first in the “race” to publish original research in a reputable 
journal. When scientists cooperate in a corporate R&D program, the main motivation 
may have more to do with financial gain. Scientific research is (ideally) long-term and 
motivated by curiosity; corporate research is short-term and profit-motivated.  But to 
what extent is this always – or even necessarily – the case? The issues here are complex. 
Might not scientists, in some circumstances, be better able to conduct basic research by 
tapping into corporate budgets? Might not the peer review process tend to encourage 
work in known areas, to the detriment of genuinely path-breaking discoveries? This 
project seeks to add to our academic understanding of these issues. 
Existing literature on this topic tends to be relatively abstract, country-specific (focusing 
mainly on U.S. conditions, e.g. Mowery et al., 2001), or highly concrete and policy-
oriented. This project seeks to bridge this gap by developing tools, based on the 
academic literature, which can be applied systematically to analyse cases in the Danish 
biotechnology industry. University-corporate cooperations can take several forms: 
patent licensing, contracts for joint development projects, physical presence in a 
corporate lab.  
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It is our working hypothesis that the dynamics of university-business partnerships will 
differ, depending, for example, on whether the scientist is involved in basic or applied 
research, product or process inventions, or according to particular areas of 
specialisation. How can such cooperations best be structured? What effects will they 
have? 
Main issues 
Several key questions arise. First, to what extent will increased patenting by university 
researchers decrease the amount of freely available public knowledge – and how will 
this affect the long-term knowledge needs of the biotechnology industry? Advances in 
this industry have traditionally been dependent on access to knowledge in the public 
domain.  
Second, how might increasing pressures to patent affect scientists’ research priorities, 
perhaps diverting research efforts away from other, possibly more academically fruitful 
lines of inquiry? In the United States, for example, leading universities increasingly use 
patent licenses to fund research. What will happen in Denmark if university budgets 
become more dependent on this source of revenue? How will this, in turn, affect 
corporate R&D programs?   
Third, patenting is costly and demanding. Companies typically contract with patent 
agents to help them apply for patents, or hire in-house patent experts. Are university 
researchers well placed to judge what is patentable and what is not? If university 
administrators step into this role, who should decide how best to proceed? Who will 
bear the costs of failed patent applications, or renewal fees for granted patents that no 
firm is interested in licensing?  
Finally, when scientists participate in commercial product development, what is the best 
way to formulate the contract between the two parties? Given the uncertainties of 
innovation, how can the parties ensure that the relationship remains flexible – and 
beneficial to both? How do venture capitalists enter into the equation? 
Research design 
As a first step, the project will summarize the nature of the central dilemmas described 
above, and the different proposed solutions, based on both findings in the international 
literature, and interviews with university researchers and administrators, corporate 
managers, and policy-makers in the international community. On this basis, the project 
will generate testable hypotheses to be applied in the Danish context.  
A questionnaire will be sent to scientists in the universities, hospitals, and other life 
sciences research institutions in Denmark, and the responses subjected to systematic 
statistical analysis. Specific questions to investigate include, for example: What is the 
relationship between the number of patents taken out by a university scientist, and the 
number of research publications? Under what circumstances does one activity support 
the other; under what circumstances is there a negative influence? In-depth, follow-up 
interviews will be conducted with selected sources in Denmark, enabling the 
formulation of proposals for reform. 
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Organization and Management in the Biotechnology Firms 
(ORG-MAN)     
Jesper Ulrik Norus  
Objectives 
The aim of the project is to explore the globalisation of firm strategies in the 
biotechnology industry and these strategies’ organisational and managerial implications. 
Recent research suggests that a small dedicated biotech firm (DBF) is best perceived as 
a loose entity, a temporary meeting place, solely defined by its portfolio of R&D 
projects and intellectual property rights in the form of patents rather than a well-defined 
unit with clear jurisdictional boundaries (Norus, 2002). Consequently DBFs are best 
analysed as loosely coupled systems and as distributed companies, where the basic 
functions and activities are decomposed and organised in external globalised networks 
(Powell, 1998). This project examines the globalisation of these networks and their 
relationships to strategies of DBFs. The two overall questions are:  
1) What are the important drivers motivating the globalisation of biotech firms?  
2) What is the role of global networks in the strategies of DBFs to mobilise scarce 
resources, such as scientific knowledge and capital?  
To study and understand the issues of globalisation in biotechnology business, the 
research agenda is broken down into five theoretical questions: 
• How is knowledge created and disseminated in distinct inter-organisational 
networks, such as communities of practice (Wenger et al., 2002)? 
• How do product development and the formation of new markets co-evolve?  
• How are managerial roles in network organisations distributed within and across 
the boundaries of the organisations? 
• How is the development of production skills, manufacturing capabilities and 
marketing functions organised in globalised strategic alliances (Powell, 1998)? 
• “Balancing local stickiness and global outlook”: How is management practiced 
so that it allow firms to undertake a dual position, being attracted and localised 
in a specific region and at the same time be connected to a globalised system of 
alliance partners (Hilpert, 2003)? 
Motivations 
The reason that this project is important is that it contributes to the ongoing research on 
the formation of innovations and new technologies. The major contribution to the 
scientific community will be the project’s strong attention on how management and 
leadership is possible in loosely coupled systems where R&D projects, capital, human 
resources and artefacts are manoeuvred in a variety of globalised strategic alliances and 
overlapping interorganisational networks. 
Scientifically this project is motivated by the source of recent research focusing on the 
competition between regions to attract and to form new biotechnology firms. Most of 
this recent research concentrates on institutional mechanisms to foster an attractive 
innovative climate and to attract companies to specific regions. The mechanisms 
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typically examined in this research are incentive schemes (tax-packages) and 
infrastructure like research parks or accessibility to knowledge from world class 
universities, the existence of a venture capital community and the location of a number 
reference industries such as pharmaceutical firms in the region (Hilpert, 2003).  Instead 
this project suggest that the role of regions and their institutional mechanisms cannot 
properly be understood without relating them to the forces of globalisation emerging 
from the network strategies of single biotech firms. Development of both biotech firms 
and regions grows out of the dual forces of regionalisation and of global networking, 
and one important motivation for this research is to understand how the two forces act 
on the individual biotech firm.  
Furthermore, results from the project may offer guidance to biotech firms on how to 
organise and monitor their numerous network relationships (alliances, research 
collaborations and agreements etc.). And they may shed light on how production skills 
are developed when a biotech firm changes from being only a research organisation to 
also being a producer. Production skills are often mobilised in external networks, based 
on formalised partnerships models, and results from this project may guide the design of 
these models. 
Research design 
The data for the research will be generated from a series of interview studies in Europe, 
US and Australia in order to develop some longitudinal case studies. This means that 
follow-up interview studies, e.g. phone interviews, have to take place during the period 
2004-2006. From the sample of cases we will identify different types of globalisation 
strategies and how these strategies develop over time. We examine what are the driving 
mechanisms behind the strategic forms of globalisation and how are globalised strategic 
alliances managed and organised. Prof. David Finegold, KGI and Jesper Norus conduct 
the project, and together they have access to several biotechnology firms around the 
globe. Finegold has contacts in America, Australia and Asia, whereas Norus’ 
experiences are mainly in the EU and the US biotechnology industries. From a sample 
of firms, this project will undertake longitudinal cross-national/cross-regional case 
studies. The reason that these cross-national studies are important is that the 
organisational dynamics in the firm’s external relationships happens rapidly both in 
time and space, and what is exchanged in the networks is often both immaterial and not 
quantifiable. This challenges research methodologies to make use of network concepts 
capable of analysing both the volatility and the stability of the interorganisational 
relationships in question. The development of the individual case studies in different 
biotechnology firms in the different locations will be carried out according to a semi-
structured interview guide. This interview guide will cover the aspects of the underlying 
research and at the same time be customised towards the different types of positions that 
the interviewees occupy in the organisations or networks investigated. 
The DABIT database that is developed by Finn Valentin in a parallel COMBI project is 
an important source of data for this part of the COMBI programme.  
Research Partnerships. 
A worldwide network of researchers will facilitate data generation in the project and 
will also provide interesting fora for research discussions about the issues of networks 
and globalisation. This primarily includes David Finegold and Steven Casper from 
Keck Graduate Institute of Applied Life Sciences; Walter Powell, Stanford University; 
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Ulrich Hilpert, Friderich Schiller Universität, Jena and Desmond Hickey, University of 
Chester, UK. Other key researchers include Malin Brännback, Turku School of 
Economics; Alan Carsrud, Florida International University; Fiona Murray, MIT; John 
Mathews, Macquarie Graduate School of Management, Sydney, Australia; and Frank 
Rothaermel, Georgia Tech. The research partnerships will be used as an opportunity to 
get access to firms in the different countries, but will also be used as an opportunity to 
develop different types of research outputs for each of the underlying research 
questions.  
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Understanding the Profitability of Danish and  
Other Biotechnology Inventions with the Help of Indicators  
(IN-PROF)          
Markus Reitzig  
 
Purpose/Objectives 
The objectives of this project are 
• To provide a large-scale empirical test of what the main determinants of the 
profitability of biotechnological inventions are, 
• To develop and refine existing indicator methods to value (portfolios of) 
biotechnology patents, and 
• To link these insights to the Danish (Southern Scandinavian) biotechnology 
sector 
Scientific motivation 
Economists have spent extensive time developing various patent indicators to measure 
innovative output (Carpenter, Cooper et al., 1980; Griliches, 1981; Narin, Noma et al., 
1987; Albert, Avery et al., 1991; Hall, Jaffe et al., 2000; Guellec and van Pottelsberghe 
de la Potterie, 2000; Reitzig, 2002). Major efforts concentrated on the compilation and 
interpretation of procedural legal information published together with the disclosure of 
the technical invention underlying the patent. Nowadays, backward citations, forward 
citations, family size, and claims (to mention but a few) are standard indicators used to 
qualify patents and weight patent counts. However, virtually all of these indicators have 
been validated in the reduced form only. This leaves economists with interpretation 
problems of empirical estimation results at various points.  
One of the fundamental remaining questions is whether certain types of patent 
indicators signal value because a) an invention is technically sophisticated, or b) 
because there is a market for it, or c) for both reasons? 
Answers to these questions are crucial for two reasons: 
• Policy makers need to understand how the adjustment of patentability 
requirements affects innovation incentives all other variables being equal, and 
• Managers and management scholars are interested in the potential of markets 
independent of the technical value of individual patent rights. 
Practical issues and concerns  
There seems to be a consensus among R&D managers, analysts, and investors that for 
various purposes valuation methods for intangible assets are needed that are 
scientifically valid and practically applicable. 
In tight appropriability regimes such as the biotechnology sector, patents represent the 
most important intangible assets of a corporation. To identify lucrative sectors for 
investment (through assessing large numbers or portfolios of patents), indicator methods 
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appear promising. However, as of today, these methods need refinement in that they 
need more theoretically based empirical validation. Despite its scientific character, this 
projects therefore simultaneously produces respective empirical evidence directly 
suitable for corporate application. 
Main Issues 
The information contents of patent indicators is complex, and the diversity of its 
potential meanings is far from being fully understood. The main caveat is that the 
information contained within patents (and respective indicators) is legal of nature and 
therefore first of all operationalises (latent) legal variables. Only through an additional 
body of theory can these indicators ultimately be linked to economic phenomena. Our 
theoretical understanding of the correlations between a patent’s observable legal 
characteristics and their economic effects, however, is still very limited. Undisputedly, 
it is true that a large variety of respective studies in this field has convincingly 
demonstrated the general suitability of procedural patent data in operationalising a 
patent’s economic value. To the best of my knowledge, however, no empirical study 
exists that allows us to interpret coefficients of patent indicators as patent value 
correlates in the structural form. From a scientific and an applied perspective, however, 
this is dissatisfying for one major reason. The reason is that for a variety of theoretical 
and practical problems, we are not only interested in whether an invention is of 
commercial value but also why it is of commercial value. This problem holds especially 
true for capital-intensive industries such as biotechnology, where complex allocation 
decisions have to be made to assure optimal investments to maximize profitability. With 
the help of custom-tailored estimation techniques, this project seeks to shed light on the 
following questions: 
• Which of the following types of value drivers affect the commercial value of 
biotechnological inventions: i) Technical quality, ii) Non-technical market 
factors, or iii) Both? 
• How can we use patent indicators correctly to estimate the value of 
biotechnological patent portfolios, hence lucrative investment sectors? 
Research Design 
This paper addresses the research problem theoretically and empirically. It starts from 
the premise (Harhoff and Reitzig, 2000) that observable oppositions against 
biotechnology patents are driven by two incentives of the opponent that are opposed 
signals of a patent’s value: 
• A low technical quality of the patent (leading to an increased likelihood of 
winning the case on the side of the opponent), and 
• A considerable commercial value of the biotechnological invention that can be 
due to various factors, technical and non-technical. 
Applying and refining a recently developed custom-tailored discrete choice estimator 
(Reitzig, 2003), reflecting the opponent’s decision making rationale, to a set of 
European biotechnology patents shall allow for a structural validation of various patent 
indicators (backward citations, forward citations, family size, and claims) and answer 
both of the above questions. In particular, the estimator disentangles the two opposed 
effects on a patent’s value underlying the opposition decision. Refinement shall be 
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carried out in cooperation with Professor Bronwyn Hall (UC Berkeley) and Professor 
Timothy Devinney (Australian Graduate School of Management) during research stays 
at the respective institutions. Finally, through econometric distinctions between Danish 
(Southern Scandinavian) and other patents, some (very preliminary) international 
benchmarking of patented Danish biotechnology with respect to technical quality and 
market attraction could emerge as well. 
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